MXPA05001649A - Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis. - Google Patents
Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.Info
- Publication number
- MXPA05001649A MXPA05001649A MXPA05001649A MXPA05001649A MXPA05001649A MX PA05001649 A MXPA05001649 A MX PA05001649A MX PA05001649 A MXPA05001649 A MX PA05001649A MX PA05001649 A MXPA05001649 A MX PA05001649A MX PA05001649 A MXPA05001649 A MX PA05001649A
- Authority
- MX
- Mexico
- Prior art keywords
- psoriasis
- treatment
- cgrp antagonist
- antagonist compounds
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5753—Calcitonin gene related peptide
Abstract
La invencion provee metodos y composiciones para tratar, prevenir y/o remediar psoriasis, basadas en compuestos que tienen un efecto antagonico del peptido relacionado con el gen de la calcitonina (CGRP). Los metodos tambien se describen para identificar compuestos con actividad antagonista del CGRP los cuales, por tanto, son compuestos candidatos adecuados para tratar la psoriasis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS6496 | 2002-08-12 | ||
PCT/IS2003/000023 WO2004014351A2 (en) | 2002-08-12 | 2003-08-12 | Use of cgrp antagonist compounds for treatment of psoriasis |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05001649A true MXPA05001649A (es) | 2005-05-27 |
Family
ID=36701412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05001649A MXPA05001649A (es) | 2002-08-12 | 2003-08-12 | Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis. |
Country Status (23)
Country | Link |
---|---|
US (5) | US20110150890A1 (es) |
EP (1) | EP1556020B1 (es) |
JP (1) | JP2006501216A (es) |
KR (1) | KR101070213B1 (es) |
CN (1) | CN1674919A (es) |
AT (1) | ATE423553T1 (es) |
AU (1) | AU2003260944B2 (es) |
BR (1) | BR0313388A (es) |
CA (1) | CA2495498C (es) |
DE (1) | DE60326370D1 (es) |
DK (1) | DK1556020T3 (es) |
EA (1) | EA008744B1 (es) |
ES (1) | ES2323170T3 (es) |
IL (1) | IL166761A (es) |
IS (1) | IS2902B (es) |
MX (1) | MXPA05001649A (es) |
NO (1) | NO20051262L (es) |
NZ (1) | NZ538615A (es) |
PL (1) | PL375536A1 (es) |
PT (1) | PT1556020E (es) |
RS (1) | RS52750B (es) |
SI (1) | SI1556020T1 (es) |
WO (1) | WO2004014351A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0313388A (pt) | 2002-08-12 | 2005-07-05 | Birkir Sveinsson | Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
ES2664421T3 (es) | 2005-11-14 | 2018-04-19 | Teva Pharmaceuticals International Gmbh | Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina |
US8293239B2 (en) | 2008-03-04 | 2012-10-23 | Pfizer Limited | Methods of treating chronic pain |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
WO2011024113A1 (en) | 2009-08-28 | 2011-03-03 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
CN108373502B (zh) | 2011-05-20 | 2022-03-22 | H.伦德贝克公司 | 抗cgrp组合物及其用途 |
CN103957935B (zh) | 2011-05-20 | 2018-04-03 | 奥尔德生物控股有限责任公司 | 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途 |
KR102098546B1 (ko) | 2011-05-20 | 2020-04-07 | 앨더바이오 홀딩스 엘엘씨 | 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도 |
JP5923375B2 (ja) * | 2012-04-24 | 2016-05-24 | 花王株式会社 | Cgrp応答性促進剤 |
DK3119431T3 (da) | 2014-03-21 | 2024-03-18 | Teva Pharmaceuticals Int Gmbh | Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
CA2960756C (en) | 2014-09-15 | 2023-08-01 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
WO2016116948A1 (en) | 2015-01-22 | 2016-07-28 | Ram Isanaka | Peptide for treating inflammatory diseases |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
WO2017001433A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
WO2017001434A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
EP3515937A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating refractory migraine |
US11433119B2 (en) | 2016-11-18 | 2022-09-06 | Nepsone Ehf | Methods of treating inflammatory skin disorders |
WO2018236873A1 (en) * | 2017-06-19 | 2018-12-27 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION |
WO2019087161A1 (en) * | 2017-11-06 | 2019-05-09 | Auckland Uniservices Limited | Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof |
KR20200139720A (ko) | 2018-04-02 | 2020-12-14 | 암젠 인크 | 에레누맙 조성물 및 이의 용도 |
WO2019213660A2 (en) * | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
US11639380B2 (en) | 2019-01-08 | 2023-05-02 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
CN111867559A (zh) * | 2019-01-25 | 2020-10-30 | 株式会社爱茉莉太平洋 | 含有苯甲酰胺化合物以及增溶剂的组合物 |
AR126954A1 (es) * | 2021-09-02 | 2023-12-06 | Biohaven Pharm Holding Co Ltd | Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7953194A (en) * | 1994-08-16 | 1996-03-07 | Human Genome Sciences, Inc. | Calcitonin receptor |
FR2729855A1 (fr) * | 1995-01-26 | 1996-08-02 | Oreal | Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue |
FR2732220B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue |
FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
EP0737471A3 (fr) | 1995-04-10 | 2000-12-06 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
EP0934068A1 (en) * | 1996-09-09 | 1999-08-11 | Smithkline Beecham Corporation | Compounds and methods |
WO1998056779A1 (en) * | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
US6214816B1 (en) * | 1998-03-17 | 2001-04-10 | Novo Nordisk A/S | Heterocyclic compounds |
ES2137136B1 (es) * | 1998-05-18 | 2000-07-01 | Esteve Labor Dr | Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica. |
WO2000018764A1 (en) | 1998-09-30 | 2000-04-06 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
CZ20032081A3 (cs) | 2001-02-01 | 2004-01-14 | Biogen, Inc. | Kombinace inhibitoru interakce CD2/LFA-3 a UVB záření pro použití při léčení kožních onemocnění |
BR0313388A (pt) | 2002-08-12 | 2005-07-05 | Birkir Sveinsson | Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
WO2009033809A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP3490581A4 (en) | 2016-07-26 | 2020-10-14 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR TREATMENT OF CANCER |
-
2003
- 2003-08-12 BR BR0313388-5A patent/BR0313388A/pt not_active Application Discontinuation
- 2003-08-12 EA EA200500306A patent/EA008744B1/ru not_active IP Right Cessation
- 2003-08-12 DK DK03784467T patent/DK1556020T3/da active
- 2003-08-12 DE DE60326370T patent/DE60326370D1/de not_active Expired - Lifetime
- 2003-08-12 RS YU20050132A patent/RS52750B/sr unknown
- 2003-08-12 KR KR1020057002417A patent/KR101070213B1/ko active IP Right Grant
- 2003-08-12 MX MXPA05001649A patent/MXPA05001649A/es active IP Right Grant
- 2003-08-12 CN CNA038194236A patent/CN1674919A/zh active Pending
- 2003-08-12 EP EP03784467A patent/EP1556020B1/en not_active Expired - Lifetime
- 2003-08-12 CA CA2495498A patent/CA2495498C/en not_active Expired - Lifetime
- 2003-08-12 AU AU2003260944A patent/AU2003260944B2/en not_active Ceased
- 2003-08-12 AT AT03784467T patent/ATE423553T1/de active
- 2003-08-12 SI SI200331590T patent/SI1556020T1/sl unknown
- 2003-08-12 PL PL03375536A patent/PL375536A1/xx not_active Application Discontinuation
- 2003-08-12 ES ES03784467T patent/ES2323170T3/es not_active Expired - Lifetime
- 2003-08-12 WO PCT/IS2003/000023 patent/WO2004014351A2/en active Application Filing
- 2003-08-12 PT PT03784467T patent/PT1556020E/pt unknown
- 2003-08-12 NZ NZ538615A patent/NZ538615A/en not_active IP Right Cessation
- 2003-08-12 JP JP2004527284A patent/JP2006501216A/ja active Pending
-
2005
- 2005-02-08 IL IL166761A patent/IL166761A/en unknown
- 2005-03-11 NO NO20051262A patent/NO20051262L/no not_active Application Discontinuation
- 2005-03-14 IS IS7741A patent/IS2902B/is unknown
-
2011
- 2011-03-02 US US13/039,075 patent/US20110150890A1/en not_active Abandoned
-
2013
- 2013-08-16 US US13/969,288 patent/US9585940B2/en active Active
-
2016
- 2016-11-18 US US15/355,723 patent/US10668132B2/en active Active
-
2020
- 2020-05-30 US US16/888,708 patent/US11266718B2/en active Active
-
2022
- 2022-10-20 US US17/969,971 patent/US20230181693A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS20050132A (en) | Use of cgrp antagonist compounds for treatment of psoriasis | |
IL280818A (en) | Methods of production of alpha-galactosides preparations | |
MXPA05001096A (es) | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. | |
TW200736231A (en) | Substituted pyrimidines | |
NO20031521D0 (no) | Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme | |
IL139080A0 (en) | Btx inhibitors and methods for their indentification and use | |
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
DE602004017494D1 (de) | Inhibitoren von p-38-kinase | |
MX2007006204A (es) | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. | |
WO2006002437A3 (en) | Treatment of conditions involving demyelination | |
ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
WO2004080425A3 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
HK1080092A1 (en) | Vegf antagonists for the treatment of diabetes | |
WO2003105840A3 (en) | SPHINGOSINE KINASE INHIBITORS | |
TR200003525T2 (tr) | Bipolar bozuklukların tedavisi için kombinasyon terapisi | |
NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
WO2001010903A3 (en) | Proteases and protease inhibitors | |
WO2004017992A3 (en) | Ptk7 protein involvement in carcinoma | |
WO2004045545A3 (en) | Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression | |
MXPA03008039A (es) | Polipeptidos de serpina humanos. | |
PL1819354T3 (pl) | Sposoby i związki do leczenia cukrzycy | |
CY1109081T1 (el) | Χρηση ενωσεων ανταγωνιστων cgrp για τη θεραπεια ψωριασης | |
WO2006034485A3 (en) | Treatment for age-related cognitive decline and other conditions | |
WO2002000840A3 (en) | Human lyases | |
WO2004048518A3 (en) | Organelle-associated proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights | ||
FG | Grant or registration |